Breaking News: Palisade Bio, Inc. (Nasdaq: PALI) Begins Dosing Ongoing Phase 1 Study—Triggering 16 Bullish Signals

*Sponsored Krypton Street Announces Its Next Potential Breakout Idea  For Friday 3/14/2025… Take A Look At Palisade Bio, Inc. (Nasdaq: PALI) While  It’s Still Early! Here’s What We Can Tell You—So Far: Limited Float: With fewer than 2.75M shares in its float, Palisade Bio, Inc. (Nasdaq: PALI) has a structure that could witness significant swings if demand begins to shift. Recent Market Recognition: Palisade Bio, Inc. (Nasdaq: PALI) has shown short-term moves, including an approximate 139% move in under 24 hours. Analyst Coverage: Brookline Capital Markets has issued a $38 target, which suggests a 4,041% upside potential from yesterday’s close. Potential Momentum: Palisade Bio, Inc. (Nasdaq: PALI) has been holding near or above key moving averages. Expanding Market: The inflammatory bowel disease treatment market is projected to reach $22B in 2025 and surpass $31B by 2034, with the U.S. market alone expected to approach $10B in 2025. Upcoming Milestones: Palisade Bio, Inc. (Nasdaq: PALI) is approaching key developments, including Phase 1 topline data expected in early 2025, Phase 1b/2a trials planned, and further pipeline advancements underway. Keep reading to see why Palisade Bio, Inc. (Nasdaq: PALI) is topping our watchlist for tomorrow morning. March 14, 2025 Dear Reader, Breaking news just crossed the wire. Palisade Bio, Inc. (Nasdaq: PALI) just announced dosing has officially begun for the first ulcerative colitis (UC) patient cohort in its ongoing Phase 1a/b study of PALI-2108.  And so far?  The data is looking strong. With all five single ascending dose (SAD) cohorts and three completed multiple ascending dose (MAD) cohorts showing a solid safety and tolerability profile, PALI-2108 continues to check all the right boxes.  No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to lab values or EKGs have been reported.  Even more impressive, one MAD cohort wrapped up with zero TEAEs—a major green flag for tolerability. Now, as Palisade Bio, Inc. (Nasdaq: PALI) transitions from healthy volunteers to actual UC patients, the anticipation is building.  The final MAD and UC cohorts are in motion, and the company remains on track to drop topline data in the first half of 2025. Adding fuel to the fire?  TradingView just lit up 16 bullish signals for Palisade Bio, Inc. (Nasdaq: PALI), including the “Momentum Indicator” on the 15-minute timeframe.   With technicals heating up and major clinical milestones ahead, Palisade Bio, Inc. (Nasdaq: PALI) is one company to have on your radar today. And once you see what the analysts are saying, you’re going to want to pay close attention this morning –3/14/2025. The biotech sector moves quickly—one announcement, a shift in momentum, or the right catalyst can turn an overlooked company into one that’s suddenly in focus. Right now, there’s a biotech company working on candidates in a market projected to exceed $22B in 2025 and grow past $31B by 2034. It’s still flying under the radar—for now.  But based on what analysts are saying, that may not last much longer.  The company?  Palisade Bio, Inc. (Nasdaq: PALI). And keep reading to see why analysts are setting targets that suggest potential upsides of over 1,400% and 4,000% from yesterday’s close. Analyst Initiates Coverage On Palisade Bio, Inc. (Nasdaq: PALI) With $38 Target… With less than 2.75M shares listed in its float, Palisade Bio (Nasdaq: PALI) is structured in a way that could see significant movement if demand begins to shift.  Palisade Bio (Nasdaq: PALI) has a market cap of just around $2.7M, a sign that it appears to be flying under the radar—but recent analyst attention suggests that might not be the case for much longer. Two firms have recently initiated coverage, issuing targets that are difficult to ignore.  Benzigna reports that Brookline Capital Markets has set a $38 target, which suggests a potential upside of 4,041% from yesterday’s $.9175 close. Meanwhile, Ladenburg Thalmann has issued a $14 target, which suggests a potential upside of 1,425%. Palisade Bio, Inc. (Nasdaq: PALI) has been trending near or above several key moving averages, showing signs that the potential for momentum may be building. 5-Day: 0.9163 20-Day: 0.9088 With its 50-Day moving average at 1.3034, 100-Day at 1.8871, and 200-Day at 2.9383, we will have all eyes on Palisade Bio, Inc. (Nasdaq: PALI) tomorrow. (Friday, 3/14/2025) Just take a look at some of Palisade Bio, Inc. (Nasdaq: PALI)’s recent overnight and multi-day moves: +139% Approx. Move: 12/11/2024 → 12/12/2024 (From $1.38 to $3.30) +46% Approx. Move: 03/04/2025 → 03/12/2025 (From $0.75 to $1.10) +37% Approx. Move: 01/03/2025 → 01/06/2025 (From $1.78 to $2.44) Keep reading to see why Palisade Bio, Inc. (Nasdaq: PALI) is topping our early watchlist this morning. Palisade Bio, Inc. (Nasdaq: PALI) – Advancing Next-Generation Therapies Palisade Bio, Inc. (Nasdaq: PALI) is a biopharmaceutical company focused on developing precision therapies for immune, inflammatory, and fibrotic diseases—areas where current treatment options often fall short. The company’s lead program, PALI-2108, is designed to target ulcerative colitis (UC), a chronic inflammatory condition affecting a large patient population worldwide.  With a gut-restricted mechanism of action, PALI-2108 aims to provide a more targeted approach with fewer systemic side effects compared to existing treatments. Palisade Bio, Inc. (Nasdaq: PALI) isn’t stopping there.  The company is also advancing PALI-1908, an early-stage therapy designed for fibrostenotic Crohn’s disease, another severe gastrointestinal condition. With a growing market and an expanding pipeline of next-generation therapies, Palisade Bio, Inc. (Nasdaq: PALI) is working to establish itself as a key player in the biotech space. A Market on Track for Significant Growth… The demand for better treatments in this space continues to rise. The global inflammatory bowel disease (IBD) treatment market is projected to exceed $22B in 2025 and grow past $31B by 2034. In the U.S. alone, the market is expected to reach nearly $10B in 2025, driven by: Increasing cases of ulcerative colitis and Crohn’s disease Demand for more effective and safer therapies Advancements in treatment options and rising healthcare spending As these conditions become more common, companies developing innovative and targeted treatments could see increasing attention in this expanding sector. How Palisade Bio, Inc. (Nasdaq: PALI) is Approaching This Market… Instead of taking a one-size-fits-all approach, Palisade Bio, Inc. (Nasdaq: PALI) is leveraging precision medicine and machine learning to develop therapies that: Target inflammation at the source → Instead of affecting the entire body like many existing therapeutics, Palisade Bio, Inc. (Nasdaq: PALI)’s therapies are designed to work directly in the gut, potentially reducing side effects. Use advanced delivery methods → PALI-2108 is a gut-restricted PDE4 inhibitor, meaning it is designed to work where the disease occurs without unnecessary exposure to the rest of the body. Leverage machine learning for patient selection → By using biomarkers, the company aims to identify patients who are most likely to respond, increasing the chances of treatment success. This approach could make PALI-2108 a strong contender in the expanding IBD treatment market. Upcoming Milestones That Could Put Palisade Bio, Inc. (Nasdaq: PALI) in the Spotlight… Palisade Bio, Inc. (Nasdaq: PALI)’s clinical progress is accelerating, with key milestones expected over the next 12 months: Phase 1 trials for PALI-2108 → All five cohorts have been dosed, with topline data expected in the first half of 2025. Phase 1b/2a trials planned → The next step in clinical development, with potential regulatory advancements ahead. Pipeline expansion → Additional therapies targeting immune, inflammatory, and fibrotic diseases are in development. With multiple catalysts on the horizon, Palisade Bio, Inc. (Nasdaq: PALI) has entered a phase where the potential for momentum could build quickly. 7 Reasons Why We Will Have All Eyes On Palisade Bio, Inc. (Nasdaq: PALI) This Morning… 1. Limited Float: With less than 2.75M shares in its float, Palisade Bio, Inc. (Nasdaq: PALI) is structured in a way that could see significant movement if demand shifts. 2. Recent Market Recognition: Palisade Bio, Inc. (Nasdaq: PALI) has shown multiple short-term moves, including an (approx.) 139% move in under 24 hours, a 46% (approx.) move in under 7 sessions and 37% (approx.) move from one session to the next.  3. Analyst Coverage: Brookline Capital Markets has set a $38 target, which suggests an upside potential of 4,041%, while Ladenburg Thalmann has issued a $14 target, which suggests an upside potential of 1,425% for Palisade Bio, Inc. (Nasdaq: PALI). 4. Potential Momentum: Palisade Bio, Inc. (Nasdaq: PALI) has been trending near or above several key moving averages, including the 5-day at 0.9163 and 20-day at 0.9088, with longer-term levels like the 50-day at 1.3034, 100-day at 1.8871, and 200-day at 2.9383 in focus—making it one to watch closely heading into tomorrow. 5. Expanding Market: The inflammatory bowel disease treatment market, where Palisade Bio, Inc. (Nasdaq: PALI) is developing next-generation therapies, is projected to reach $22B in 2025 and grow beyond $31B by 2034, with the U.S. market alone expected to approach $10B in 2025. 6. Precision Medicine Approach: Palisade Bio, Inc. (Nasdaq: PALI) is developing PALI-2108, a therapy designed to target inflammation at the source using gut-restricted delivery, machine learning for patient selection, and a next-generation approach to treatment. 7. Upcoming Milestones: Palisade Bio, Inc. (Nasdaq: PALI) is approaching key catalysts, including Phase 1 topline data expected in early 2025, Phase 1b/2a trials planned, and additional pipeline developments underway. Consider Adding Palisade Bio, Inc. (Nasdaq: PALI) To Your Radar This Morning… Let’s be real—low-float biotech companies with high volatility, fresh analyst coverage, and upcoming milestones don’t just slip under the radar forever. With a float of less than 2.75M shares, recent approximate moves exceeding 100% in a single session, and coverage suggesting significant upside potential, Palisade Bio, Inc. (Nasdaq: PALI) is looking more and more like something that won’t stay overlooked for long. We have all eyes on (PALI) this morning.  Consider taking a look at (PALI) before the bell rings. Palisade Bio, Inc. (Nasdaq: PALI) just lit up 16 bullish signals for Palisade Bio, Inc. (Nasdaq: PALI), including the “Momentum Indicator” on the 15-minute timeframe.  I’ll follow up with you shortly. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: kryptonstreet.com/disclaimer/ *Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 03/11/2025 and ending on 03/14/2025 to publicly disseminate information about (PALI:US) via digital communications. Under this agreement, Media 1717 LLC has been paid seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Media 1717 LLC, TD Media LLC, or their members own shares of (PALI:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/pali/#details

Media 1717 LLC | 6586 W Atlantic Ave Unit #2086 | Delray Beach, FL 33446 US Unsubscribe | Update Profile | Constant Contact Data Notice